Monocarboxylate transporter 1 inhibitors as potential anticancer agents

Shirisha Gurrapu, Sravan K. Jonnalagadda, Mohammad A. Alam, Grady L. Nelson, Mary G. Sneve, Lester R Drewes, Venkatram R Mereddy

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


Potent monocarboxylate transporter 1 inhibitors (MCT1) have been developed based on α-cyano-4-hydroxycinnamic acid template. Structure-activity relationship studies demonstrate that the introduction of p-N, N-dialkyl/diaryl, and o-methoxy groups into cyanocinnamic acid has maximal MCT1 inhibitory activity. Systemic toxicity studies in healthy ICR mice with few potent MCT1 inhibitors indicate normal body weight gains in treated animals. In vivo tumor growth inhibition studies in colorectal adenocarcinoma (WiDr cell line) in nude mice xenograft models establish that compound 27 exhibits single agent activity in inhibiting the tumor growth.

Original languageEnglish (US)
Pages (from-to)558-561
Number of pages4
JournalACS Medicinal Chemistry Letters
Issue number5
StatePublished - May 14 2015

Bibliographical note

Publisher Copyright:
© 2015 American Chemical Society.


  • Warburg effect
  • colorectal adenocarcinoma
  • monocarboxylate transporter 1
  • reverse Warburg effect
  • α-cyano-4-hydroxycinnamic acid


Dive into the research topics of 'Monocarboxylate transporter 1 inhibitors as potential anticancer agents'. Together they form a unique fingerprint.

Cite this